A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Tag: Theranostics
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
Building better bubbles for ultrasound could enhance image quality, facilitate treatments
NIBIB-funded researchers are investigating long-lasting, customizable nanobubbles for ultrasound contrast agents.
SOFIE And University Clinic Heidelberg Sign License Agreement For Theranostics That Target Cancer Associated Fibroblasts
LOS ANGELES and HEIDELBERG, Germany, June 21, 2019 /PRNewswire/ — SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics (“theranostics”) that are…